Home > Search Clinical Trials > Cancer - Multiple Myeloma

IRB No. U26-002-1 (Dr. Swarup Kumar, PI): A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

The purpose of this study is to compare Teclistamab in Combination with Daratumumab Subcutaneous (SC) and Lenalidomide (Tec-DR), Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy.

IRB No. U26-139-1 (Dr. Swarup Kumar, PI): A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma

The purpose of this study is to compare the effects of the investigational drug, called JNJ-79635322, with the BCMAxCD3 bispecific antibody, called Teclistamab, after at least 3 prior lines of therapy in patients with multiple myeloma.